{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+%28Phase+1%29&page=56",
    "query": {
      "condition": "Advanced Solid Tumor (Phase 1)",
      "page": 56
    },
    "page_size": 10
  },
  "pagination": {
    "page": 56,
    "page_size": 10,
    "total_count": 2486,
    "total_pages": 249,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+%28Phase+1%29&page=57&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumor+%28Phase+1%29&page=55&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-20T13:52:57.404Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01061788",
      "title": "A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors, Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "AMG 479, Everolimus, Panitumumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey Clarke",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 43,
      "start_date": "2010-04",
      "completion_date": "2018-12-19",
      "has_results": false,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-11-20T13:52:57.404Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01061788"
    },
    {
      "nct_id": "NCT00861328",
      "title": "Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ON 01910.Na and irinotecan",
          "type": "DRUG"
        },
        {
          "name": "ON 01910.Na and oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Traws Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2008-02",
      "completion_date": "2011-07",
      "has_results": false,
      "last_update_posted_date": "2017-06-23",
      "last_synced_at": "2026-11-20T13:52:57.404Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00861328"
    },
    {
      "nct_id": "NCT00437203",
      "title": "PF-00477736 Is Being Studied In Advanced Solid Tumors In Combination With Chemotherapy With Gemcitabine",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "PF-00477736",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2006-12",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2012-04-03",
      "last_synced_at": "2026-11-20T13:52:57.404Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Santa Monica, California • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00437203"
    },
    {
      "nct_id": "NCT01625156",
      "title": "Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adult Solid Neoplasm"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Tivantinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 11,
      "start_date": "2012-05",
      "completion_date": "2015-10",
      "has_results": false,
      "last_update_posted_date": "2015-10-20",
      "last_synced_at": "2026-11-20T13:52:57.404Z",
      "location_count": 2,
      "location_summary": "Madison, Wisconsin • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01625156"
    },
    {
      "nct_id": "NCT01577745",
      "title": "A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "MEDI0639",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 58,
      "start_date": "2012-04",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2017-05-02",
      "last_synced_at": "2026-11-20T13:52:57.404Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • New Haven, Connecticut • Boston, Massachusetts + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01577745"
    },
    {
      "nct_id": "NCT00112892",
      "title": "Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "selenium",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "irinotecan hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2004-08",
      "completion_date": "2007-12",
      "has_results": false,
      "last_update_posted_date": "2014-01-13",
      "last_synced_at": "2026-11-20T13:52:57.404Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00112892"
    },
    {
      "nct_id": "NCT05614739",
      "title": "FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urinary Bladder Neoplasms",
        "Neoplasm Metastasis",
        "Ureteral Neoplasms"
      ],
      "interventions": [
        {
          "name": "Vepugratinib",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "enfortumab vedotin",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab Deruxtecan",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Digoxin",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 677,
      "start_date": "2023-01-12",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-11-04",
      "last_synced_at": "2026-11-20T13:52:57.404Z",
      "location_count": 41,
      "location_summary": "Tucson, Arizona • Duarte, California • Los Angeles, California + 29 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05614739"
    },
    {
      "nct_id": "NCT03538028",
      "title": "A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Cancer",
        "Microsatellite Instability (MSI)-High Endometrial Cancer",
        "Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ])",
        "Esophageal Cancer",
        "Hepatocellular Carcinoma",
        "Melanoma (Uveal Melanoma Excluded)",
        "Merkel Cell Carcinoma",
        "Mesothelioma",
        "MSI-high Colorectal Cancer",
        "Non-small Cell Lung Cancer (NSCLC)",
        "Ovarian Cancer",
        "Squamous Cell Carcinoma of the Head and Neck (SCCHN)",
        "Small Cell Lung Cancer (SCLC)",
        "Renal Cell Carcinoma (RCC)",
        "Triple-negative Breast Cancer",
        "Urothelial Carcinoma",
        "Diffuse Large B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "INCAGN02385",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Incyte Biosciences International Sàrl",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2018-06-18",
      "completion_date": "2020-10-07",
      "has_results": false,
      "last_update_posted_date": "2020-10-30",
      "last_synced_at": "2026-11-20T13:52:57.404Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Hackensack, New Jersey • Huntersville, North Carolina + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03538028"
    },
    {
      "nct_id": "NCT04418167",
      "title": "JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "JSI-1187",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "JS InnoPharm, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2020-06-18",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2025-09-03",
      "last_synced_at": "2026-11-20T13:52:57.404Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • San Francisco, California + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04418167"
    },
    {
      "nct_id": "NCT00613145",
      "title": "Study of the Pharmacokinetics/Safety of Sorafenib + Capecitabine in Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Refractory Malignancy"
      ],
      "interventions": [
        {
          "name": "Capecitabine and Sorafenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SCRI Development Innovations, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2008-02",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2013-02-04",
      "last_synced_at": "2026-11-20T13:52:57.404Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00613145"
    }
  ]
}